Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate 
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns 
Hims & Hers Halts Compounded Semaglutide Pill After FDA Warning 
Instagram Outage Disrupts Thousands of U.S. Users 
Alphabet’s Massive AI Spending Surge Signals Confidence in Google’s Growth Engine 
SpaceX Pushes for Early Stock Index Inclusion Ahead of Potential Record-Breaking IPO 
SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off 
Nasdaq Proposes Fast-Track Rule to Accelerate Index Inclusion for Major New Listings 
Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil 
Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing 
Trump Backs Nexstar–Tegna Merger Amid Shifting U.S. Media Landscape 
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies 
Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch 
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge 
TSMC Eyes 3nm Chip Production in Japan with $17 Billion Kumamoto Investment 
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans 
Baidu Approves $5 Billion Share Buyback and Plans First-Ever Dividend in 2026 
- Webcast to be held Thursday, October 6, 2016 at 11:00 a.m. ET
STAMFORD, Conn., Oct. 03, 2016 -- Cara Therapeutics, Inc. (Nasdaq:CARA), a biotechnology company focused on developing and commercializing new chemical entities designed to alleviate pain and pruritus by selectively targeting peripheral kappa opioid receptors, today announced that Dr. Derek Chalmers, President and Chief Executive Officer, will participate in a webcast featuring innovations in pain management therapies. The webcast is part of a series from Biopharma Dealmakers, a quarterly supplement in Nature Biotechnology and Nature Reviews Drug Discovery.
Four companies that are working to address unmet needs in pain management will present their developments, which include analgesics with novel mechanisms of action, medical devices, and opioids with reduced potential for abuse and physical dependence. The webcast will also include a roundtable discussion and a question and answer session with Dr. Chalmers and the other speakers.
Details for the webcast are as follows:
Date: Thursday, October 6, 2016
Time: 11:00 a.m. ET
Moderator: Raveena Bhambra, Editor of BioPharma Dealmakers
Participants:
- Dr. Derek Chalmers, President and CEO of Cara Therapeutics
- Dr. Jeffrey Herz, President and CEO of Algomedix, Inc.
- Dr. Jessica Preciado, Director of Product Development and Principal Scientist of Myoscience
- Dr. Steve Doberstein, Senior Vice President and Chief Scientific Officer of Nektar Therapeutics
For more information, and to register for this free webcast, visit: http://www.workcast.com/register?cpak=5922214840089056&referrer=SPONSOR_CaraTherapeutics.
About Cara Therapeutics
Cara Therapeutics is a clinical-stage biotechnology company focused on developing and commercializing new chemical entities designed to alleviate pain and pruritus by selectively targeting peripheral kappa opioid receptors. Cara is developing a novel and proprietary class of product candidates that target the body's peripheral nervous system and have demonstrated initial efficacy in patients with moderate-to-severe pain without inducing many of the undesirable side effects typically associated with currently available pain therapeutics.
INVESTOR CONTACT: Jesse Baumgartner Stern Investor Relations, Inc. 212-362-1200 [email protected] MEDIA CONTACT: Annie Starr 6 Degrees 973-415-8838 [email protected]
